A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact (ENCORE)
The main objective of this study is to evaluate the efficacy of ALIS (amikacin liposome
inhalation suspension) + background regimen (azithromycin [AZI] + ethambutol [ETH]) compared
to the ELC (empty liposome control) + background regimen on participant-reported respiratory
symptoms at Month 13.
Mycobacterium Infections, Nontuberculous
ELC (matching placebo for ALIS)
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.